AVTE

Aerovate Therapeutics, Inc.

1.41 USD
-0.24 (-14.55%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aerovate Therapeutics, Inc. stock is down -93.01% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 3 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 10 PUTs. 40% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 Jun 13:38 21 Jun, 2024 5.00 PUT 100 1753
17 Jun 13:40 21 Jun, 2024 7.50 PUT 52 1854
17 Jun 13:52 21 Jun, 2024 5.00 PUT 100 1753
17 Jun 14:19 19 Jul, 2024 10.00 PUT 40 791
17 Jun 15:11 21 Jun, 2024 7.50 PUT 163 1854
17 Jun 15:43 15 Nov, 2024 25.00 PUT 12 12
17 Jun 19:11 21 Jun, 2024 22.50 PUT 30 26
17 Jun 19:46 19 Jul, 2024 10.00 PUT 31 791
18 Jun 14:33 15 Nov, 2024 30.00 PUT 10 11
18 Jun 15:31 19 Jul, 2024 15.00 PUT 88 269

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc. focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company is advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

  • TD Cowen
    Tue Jun 18, 05:40
    hold
    downgrade
  • Jefferies
    Mon Jun 17, 14:21
    hold
    downgrade
  • BTIG
    Mon Jun 17, 13:06
    hold
    downgrade
  • Wedbush
    Thu Jun 6, 09:51
    buy
    confirm
  • Wedbush
    Wed May 22, 10:56
    buy
    confirm